CL2014003455A1 - Método para inhibir activación del complemento dependiente de masp-3 y, opcionalmente masp-1 y masp-2, para el tratamiento de diversas enfermedades y trastornos. - Google Patents

Método para inhibir activación del complemento dependiente de masp-3 y, opcionalmente masp-1 y masp-2, para el tratamiento de diversas enfermedades y trastornos.

Info

Publication number: CL2014003455A1
Authority: CL; Chile
Prior art keywords: masp; disorders; treatment; optionally; various diseases
Prior art date: 2012-06-18

Application number

CL2014003455A

Other languages

English (en)

Inventor

Gregory A Demopulos

Hans Wilhelm Schwaeble

Thomas Dudler

Patrick Gray

Original Assignee

Omeros Corp

Univ Leicester

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-18

Filing date

2014-12-18

Publication date

2015-04-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49769678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003455(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-12-18 Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp

2015-04-10 Publication of CL2014003455A1 publication Critical patent/CL2014003455A1/es

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Hematology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Mycology (AREA)
Ophthalmology & Optometry (AREA)
Tropical Medicine & Parasitology (AREA)
Rheumatology (AREA)
Gastroenterology & Hepatology (AREA)
Transplantation (AREA)
Toxicology (AREA)
Virology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)

CL2014003455A 2012-06-18 2014-12-18 Método para inhibir activación del complemento dependiente de masp-3 y, opcionalmente masp-1 y masp-2, para el tratamiento de diversas enfermedades y trastornos. CL2014003455A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201261661167P	2012-06-18	2012-06-18

Publications (1)

Publication Number	Publication Date
CL2014003455A1 true CL2014003455A1 (es)	2015-04-10

Family

ID=49769678

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CL2014003455A CL2014003455A1 (es)	2012-06-18	2014-12-18	Método para inhibir activación del complemento dependiente de masp-3 y, opcionalmente masp-1 y masp-2, para el tratamiento de diversas enfermedades y trastornos.
CL2016003297A CL2016003297A1 (es)	2012-06-18	2016-12-22	Composiciones y métodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de diversas enfermedades y trastornos. (divisional solicitud 3455-2014)

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CL2016003297A CL2016003297A1 (es)	2012-06-18	2016-12-22	Composiciones y métodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de diversas enfermedades y trastornos. (divisional solicitud 3455-2014)

Country Status (26)

Country	Link
US (6)	US20130344073A1 (es)
EP (5)	EP3878865A3 (es)
JP (6)	JP6445972B2 (es)
KR (4)	KR102339315B1 (es)
CN (4)	CN115040653A (es)
AU (3)	AU2013277309B2 (es)
BR (1)	BR112014031522A2 (es)
CA (2)	CA3214532A1 (es)
CL (2)	CL2014003455A1 (es)
CY (1)	CY1124234T1 (es)
DK (1)	DK2861246T3 (es)
ES (1)	ES2864857T3 (es)
HR (1)	HRP20210559T1 (es)
HU (1)	HUE053727T2 (es)
IL (2)	IL236327B (es)
IN (1)	IN2015KN00015A (es)
LT (1)	LT2861246T (es)
MX (4)	MX381048B (es)
NZ (1)	NZ629473A (es)
PL (1)	PL2861246T3 (es)
PT (1)	PT2861246T (es)
RS (1)	RS61755B1 (es)
RU (2)	RU2019140356A (es)
SI (1)	SI2861246T1 (es)
WO (1)	WO2013192240A2 (es)
ZA (1)	ZA201500094B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8937046B2 (en)	2008-09-22	2015-01-20	The Regents Of The University Of Colorado, A Body Corporate	Modulating the alternative complement pathway
BR112013025917A2 (pt)	2011-04-08	2016-12-20	Omeros Corp	uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2
WO2014030750A1 (ja)	2012-08-24	2014-02-27	中外製薬株式会社	マウスFcγRII特異的Fc抗体
US9217042B2 (en) *	2012-10-23	2015-12-22	Abbott Cardiovascular Systems Inc.	Method of reducing MACE in diabetic patients subsequent to stent placement
US20140363433A1 (en)	2013-03-15	2014-12-11	Omeros Corporation	Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
NZ629682A (en)	2013-03-15	2017-03-31	Omeros Corp	Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
CN105246914B (zh)	2013-04-02	2021-08-27	中外制药株式会社	Fc区变体
EP2983710B1 (en) *	2013-04-09	2019-07-31	Annexon, Inc.	Methods of treatment for neuromyelitis optica
US10183988B2 (en)	2013-06-07	2019-01-22	Duke University	Anti-Complement factor H antibodies
DK3019240T3 (da)	2013-07-09	2024-06-03	Annexon Inc	Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
JP2016539919A (ja)	2013-10-17	2016-12-22	オメロスコーポレーション	Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法
US10155983B2 (en)	2014-03-31	2018-12-18	Machaon Diagnostics, Inc.	Method of diagnosis of complement-mediated thrombotic microangiopathies
WO2015187992A2 (en) *	2014-06-05	2015-12-10	The Regents Of The University Of Colorado, A Body Corporate	Map44 polypeptides and constructs based on natural antibodies and uses thereof
SI3215527T1 (sl)	2014-11-05	2025-04-30	Annexon, Inc.	Humanizirana protitelesa proti komplementnemu faktorju C1q in njihova uporaba
WO2016186994A1 (en) *	2015-05-15	2016-11-24	Children's Medical Center Corporation	Methods relating to the diagnosis and treatment of thrombotic microangiopathy
US20180292388A1 (en) *	2015-06-03	2018-10-11	Coyne Ip Holdings, Llc	Methods for Establishing Threshold Limits for a Chemical or Biological Agent in a Target Species
WO2017035401A1 (en)	2015-08-26	2017-03-02	Achillion Pharmaceuticals, Inc.	Amide compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) *	2015-08-26	2017-12-06	Achillion Pharmaceuticals Inc	Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035405A1 (en)	2015-08-26	2017-03-02	Achillion Pharmaceuticals, Inc.	Amino compounds for treatment of immune and inflammatory disorders
WO2017035409A1 (en)	2015-08-26	2017-03-02	Achillion Pharmaceuticals, Inc.	Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
AU2016354117B2 (en) *	2015-11-09	2019-11-28	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
EP3380518B1 (en)	2015-11-24	2026-03-25	Annexon, Inc.	Anti-complement factor c1q fab fragments and uses thereof
KR102528260B1 (ko) *	2016-01-05	2023-05-04	유니버시티 오브 레스터	필요로 하는 대상체에서 섬유증의 억제 방법
MX2018011648A (es)	2016-03-31	2019-01-30	Omeros Corp	Metodos para la inhibicion de fibrosis en un sujeto en necesidad del mismo.
JOP20170154B1 (ar) *	2016-08-01	2023-03-28	Omeros Corp	تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
JOP20170170B1 (ar)	2016-08-31	2022-09-15	Omeros Corp	صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
CN110603252A (zh)	2017-03-01	2019-12-20	艾其林医药公司	用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
EP3589287B1 (en)	2017-03-01	2022-09-14	Achillion Pharmaceuticals, Inc.	Macrocyclic compounds for treatment of medical disorders
WO2018160891A1 (en)	2017-03-01	2018-09-07	Achillion Pharmaceutical, Inc.	Pharmaceutical compounds for treatment of medical disorders
WO2018186322A1 (en) *	2017-04-03	2018-10-11	Chugai Seiyaku Kabushiki Kaisha	Anti-masp-1 antibodies and methods of use
KR20200037863A (ko) *	2017-08-25	2020-04-09	오메로스 코포레이션	고도로 농축된 저점도 masp-2 억제 항체 제제, 키트, 및 비정형 용혈성 증후군을 앓고 있는 대상체의 치료 방법
EP4640703A3 (en)	2017-11-14	2026-04-08	Chugai Seiyaku Kabushiki Kaisha	Anti-c1s antibodies and methods of use
EP3774892A4 (en) *	2018-04-13	2022-02-16	Chugai Seiyaku Kabushiki Kaisha	ANTI-COMPLEMENT COMPONENT ANTIBODIES AND METHODS OF USE
IL311042B1 (en)	2018-05-29	2026-04-01	Omeros Corp	MASP-2 inhibitors and methods of use
BR112020025841A2 (pt) *	2018-06-22	2021-03-23	Omeros Corporation	método para prevenir, reduzir e/ou tratar uma doença, distúrbio ou condição associada à ativação induzida por fibrina do sistema complemento e à ativação associada dos sistemas de coagulação e/ou contato
WO2020051538A1 (en)	2018-09-06	2020-03-12	Achillion Pharmaceuticals, Inc.	Morphic forms of complement factor d inhibitors
JP7443375B2 (ja)	2018-09-06	2024-03-05	アキリオンファーマシューティカルズ，インコーポレーテッド	医学的障害の治療のための大環状化合物
KR20210093855A (ko)	2018-09-25	2021-07-28	아칠리온 파르마세우티칼스 인코포레이티드	보체 인자 d 억제제의 형태체 형태
GB2583560A (en)	2018-12-11	2020-11-04	Admirx Inc	Fusion protein constructs for complement associated disease
WO2020131974A1 (en)	2018-12-17	2020-06-25	Achillion Pharmaceuticals, Inc.	Targeted dosing for the treatment of complement mediated disorders
BR112021018456A2 (pt)	2019-03-22	2021-11-23	Achillion Pharmaceuticals Inc	Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento
MX2021013616A (es) *	2019-05-07	2021-12-10	Bayer Ag	Compuestos inhibidores de la masp y usos de estos.
EP4696320A2 (en)	2019-05-15	2026-02-18	Chugai Seiyaku Kabushiki Kaisha	Anti-c1s antibody
BR112022007051A2 (pt) *	2019-10-17	2022-07-05	Annexon Inc	Composições e métodos para tratamento de distúrbios hematológicos
EP4069676A1 (en)	2019-12-04	2022-10-12	Omeros Corporation	Masp-2 inhibitors and methods of use
BR112022010895A2 (pt)	2019-12-04	2022-09-06	Omeros Corp	Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan
IL293588B1 (en)	2019-12-04	2026-04-01	Omeros Corp	3-Amino-1-methylpyrazin-2(H1)-one derivatives as MASP-2 inhibitors, compositions containing them and uses thereof
EP4069678A1 (en)	2019-12-04	2022-10-12	Omeros Corporation	Masp-2 inhibitors and methods of use
CN112237630A (zh) *	2020-02-21	2021-01-19	中国人民解放军军事科学院军事医学研究院	针对masp-2、冠状病毒n蛋白或其结合的物质在制备冠状病毒所致疾病药物中的应用
TWI834025B (zh) *	2020-03-06	2024-03-01	美商奥默羅斯公司	用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法
JP7634082B2 (ja)	2020-08-18	2025-02-20	オメロスコーポレーション	補体因子ｄを検出するためのモノクローナル抗体、組成物、および方法
CN115215937B (zh)	2021-04-15	2023-05-26	上海麦济生物技术有限公司	抗人masp-2抗体及其制备方法和应用
US20230265215A1 (en)	2021-12-10	2023-08-24	Omeros Corporation	Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
US12486322B2 (en)	2021-12-13	2025-12-02	Annexon, Inc.	Anti-complement factor C1q antibodies with single binding arms and uses thereof
CN114989259B (zh) *	2022-05-27	2023-06-09	成都佩德生物医药有限公司	一种小分子肽Ped4及应用
CN115125299A (zh) *	2022-08-09	2022-09-30	大连珍奥药业股份有限公司	Masp1在筛选预防和/或治疗心血管疾病的药物中的应用
EP4626891A1 (en)	2022-11-30	2025-10-08	Omeros Corporation	Fused pyrimidines as masp-2 inhibitors
EP4677366A1 (en) *	2023-03-03	2026-01-14	The City University Of New York	Use of extracellular vesicles as biomarkers for age-related macular degeneration
US20250122225A1 (en)	2023-10-06	2025-04-17	Omeros Corporation	Masp-2 inhibitors and methods of use

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4331647A (en)	1980-03-03	1982-05-25	Goldenberg Milton David	Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5211657A (en)	1988-11-07	1993-05-18	The United States Government As Represented By The Secretary Of The Department Of Health And Human Services	Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5549910A (en)	1989-03-31	1996-08-27	The Regents Of The University Of California	Preparation of liposome and lipid complex compositions
EP0438803B1 (en)	1990-01-26	1997-03-12	Immunomedics, Inc.	Vaccines against cancer and infectious diseases
JP3218637B2 (ja)	1990-07-26	2001-10-15	大正製薬株式会社	安定なリポソーム水懸濁液
JP2958076B2 (ja)	1990-08-27	1999-10-06	株式会社ビタミン研究所	遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
ES2156149T3 (es)	1992-12-04	2001-06-16	Medical Res Council	Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
US5856121A (en)	1994-02-24	1999-01-05	Case Western Reserve University	Growth arrest homebox gene
US6074642A (en)	1994-05-02	2000-06-13	Alexion Pharmaceuticals, Inc.	Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5741516A (en)	1994-06-20	1998-04-21	Inex Pharmaceuticals Corporation	Sphingosomes for enhanced drug delivery
US5795587A (en)	1995-01-23	1998-08-18	University Of Pittsburgh	Stable lipid-comprising drug delivery complexes and methods for their production
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5738868A (en)	1995-07-18	1998-04-14	Lipogenics Ltd.	Liposome compositions and kits therefor
CN1433466A (zh) *	1999-12-02	2003-07-30	詹斯·C·詹斯尼厄斯	Masp－3,一种固定补体的酶,及其应用
SG98393A1 (en)	2000-05-19	2003-09-19	Inst Materials Research & Eng	Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
AU2003215524A1 (en) *	2002-03-15	2003-09-29	Natimmune A/S	Pharmaceutical compositions comprising mannose binding lectin
ES2601143T3 (es)	2002-07-19	2017-02-14	Omeros Corporation	Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos
US7666627B2 (en) *	2002-08-08	2010-02-23	Targetex Kft.	Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
US20060140939A1 (en) *	2003-02-21	2006-06-29	Fung Sek C M	Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
ES2360399T3 (es) *	2003-07-08	2011-06-03	Umc Utrecht Holding B.V.	Uso terapéutico de lpi, un inhibidor de la vía de las lectinas de origen estafilocócico, en enfermedades inflamatorias.
US7919094B2 (en)	2004-06-10	2011-04-05	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) *	2004-06-10	2014-09-23	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
ES2631127T3 (es) *	2004-06-10	2017-08-28	Omeros Corporation	Métodos para tratar afecciones asociadas con la activación del complemento dependiente de MASP-2
CN100518905C (zh) *	2004-11-02	2009-07-29	浙江欧美环境工程有限公司	折返式电除盐器
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
NZ612578A (en)	2005-08-19	2014-11-28	Abbvie Inc	Dual variable domain immunoglobin and uses thereof
JP5219819B2 (ja) *	2005-10-21	2013-06-26	カタリスト・バイオサイエンシーズ・インコーポレイテッド	補体活性化を阻害する修飾プロテアーゼ
NZ571791A (en) *	2006-03-08	2012-03-30	Archemix Llc	Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
JP5537420B2 (ja)	2007-05-31	2014-07-02	ユニヴァーシティオブワシントン	標的遺伝子の誘導性変異誘発
CA2742802C (en) *	2008-11-10	2019-11-26	Alexion Pharmaceuticals, Inc.	Methods and compositions for treating complement-associated disorders
CA2766565A1 (en) *	2009-06-23	2010-12-29	Alexion Pharmaceuticals, Inc.	Bispecific antibodies that bind to complement proteins
US20120282285A1 (en) *	2009-07-17	2012-11-08	Rigshospitalet	Masp isoforms as inhibitors of complement activation
DK2488203T3 (en) *	2009-10-16	2017-03-13	Omeros Corp	METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
US9815876B2 (en) *	2010-03-05	2017-11-14	Omeros Corporation	Chimeric inhibitor molecules of complement activation
US8795973B2 (en) *	2010-11-29	2014-08-05	University of Leceister	Methods for identifying inhibitors of mannan-binding lectin associated serine protease (MASP) proteins and uses thereof
BR112013025917A2 (pt) *	2011-04-08	2016-12-20	Omeros Corp	uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2
MX357540B (es) *	2012-04-06	2018-07-13	Omeros Corp	Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de la hemoglobinuria paroxistica nocturna.
JOP20170154B1 (ar) *	2016-08-01	2023-03-28	Omeros Corp	تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة

2013
- 2013-06-18 BR BR112014031522A patent/BR112014031522A2/pt not_active Application Discontinuation
- 2013-06-18 CN CN202210652007.6A patent/CN115040653A/zh active Pending
- 2013-06-18 CN CN202410989581.XA patent/CN118924900A/zh active Pending
- 2013-06-18 IN IN15KON2015 patent/IN2015KN00015A/en unknown
- 2013-06-18 US US13/921,139 patent/US20130344073A1/en not_active Abandoned
- 2013-06-18 KR KR1020207027432A patent/KR102339315B1/ko active Active
- 2013-06-18 PL PL13807326T patent/PL2861246T3/pl unknown
- 2013-06-18 JP JP2015518524A patent/JP6445972B2/ja active Active
- 2013-06-18 CN CN201380044434.5A patent/CN104717975A/zh active Pending
- 2013-06-18 KR KR1020207003537A patent/KR20200015952A/ko not_active Ceased
- 2013-06-18 DK DK13807326.7T patent/DK2861246T3/da active
- 2013-06-18 HU HUE13807326A patent/HUE053727T2/hu unknown
- 2013-06-18 EP EP21152111.7A patent/EP3878865A3/en not_active Withdrawn
- 2013-06-18 LT LTEP13807326.7T patent/LT2861246T/lt unknown
- 2013-06-18 WO PCT/US2013/046432 patent/WO2013192240A2/en not_active Ceased
- 2013-06-18 EP EP16150858.5A patent/EP3058951A1/en not_active Withdrawn
- 2013-06-18 AU AU2013277309A patent/AU2013277309B2/en active Active
- 2013-06-18 MX MX2014015715A patent/MX381048B/es unknown
- 2013-06-18 ES ES13807326T patent/ES2864857T3/es active Active
- 2013-06-18 RS RS20210465A patent/RS61755B1/sr unknown
- 2013-06-18 CN CN201811331359.1A patent/CN109908352A/zh active Pending
- 2013-06-18 NZ NZ629473A patent/NZ629473A/en unknown
- 2013-06-18 EP EP22177615.6A patent/EP4119577A3/en active Pending
- 2013-06-18 KR KR1020227022627A patent/KR20220100997A/ko not_active Ceased
- 2013-06-18 CA CA3214532A patent/CA3214532A1/en active Pending
- 2013-06-18 SI SI201331873T patent/SI2861246T1/sl unknown
- 2013-06-18 PT PT138073267T patent/PT2861246T/pt unknown
- 2013-06-18 CA CA2875567A patent/CA2875567C/en active Active
- 2013-06-18 HR HRP20210559TT patent/HRP20210559T1/hr unknown
- 2013-06-18 EP EP13807326.7A patent/EP2861246B1/en active Active
- 2013-06-18 RU RU2019140356A patent/RU2019140356A/ru unknown
- 2013-06-18 RU RU2015101230A patent/RU2709351C2/ru active
- 2013-06-18 EP EP25210227.2A patent/EP4659763A3/en active Pending
- 2013-06-18 KR KR20157001304A patent/KR20150031298A/ko not_active Ceased
2014
- 2014-12-17 MX MX2019012909A patent/MX2019012909A/es unknown
- 2014-12-17 MX MX2024005899A patent/MX2024005899A/es unknown
- 2014-12-17 IL IL236327A patent/IL236327B/en active IP Right Grant
- 2014-12-17 MX MX2020005700A patent/MX2020005700A/es unknown
- 2014-12-18 CL CL2014003455A patent/CL2014003455A1/es unknown
2015
- 2015-01-07 ZA ZA2015/00094A patent/ZA201500094B/en unknown
2016
- 2016-12-22 CL CL2016003297A patent/CL2016003297A1/es unknown
2018
- 2018-06-15 AU AU2018204285A patent/AU2018204285B2/en active Active
- 2018-08-28 IL IL261436A patent/IL261436B/en unknown
- 2018-09-14 US US16/131,871 patent/US20190127484A1/en not_active Abandoned
- 2018-11-30 JP JP2018224961A patent/JP6771531B2/ja active Active
2020
- 2020-05-06 AU AU2020202999A patent/AU2020202999B2/en active Active
- 2020-09-29 JP JP2020163180A patent/JP2021006546A/ja active Pending
2021
- 2021-04-20 CY CY20211100342T patent/CY1124234T1/el unknown
- 2021-10-11 US US17/498,559 patent/US20220259325A1/en not_active Abandoned
2022
- 2022-04-01 JP JP2022062008A patent/JP7839502B2/ja active Active
2023
- 2023-09-26 US US18/474,862 patent/US20240254257A1/en not_active Abandoned
2024
- 2024-04-24 JP JP2024070206A patent/JP2024099699A/ja active Pending
2025
- 2025-09-29 US US19/343,149 patent/US20260035483A1/en active Pending
- 2025-10-17 US US19/361,836 patent/US20260049158A1/en active Pending
- 2025-11-14 JP JP2025194870A patent/JP2026021601A/ja active Pending

Also Published As

Publication number	Publication date
JP2022084946A (ja)	2022-06-07
ZA201500094B (en)	2019-08-28
JP6771531B2 (ja)	2020-10-21
HK1209623A1 (zh)	2016-04-08
MX2019012909A (es)	2020-12-10
MX2024005899A (es)	2024-05-30
WO2013192240A2 (en)	2013-12-27
EP4119577A2 (en)	2023-01-18
EP4119577A3 (en)	2023-11-08
NZ728179A (en)	2021-12-24
JP2024099699A (ja)	2024-07-25
EP3058951A1 (en)	2016-08-24
US20190127484A1 (en)	2019-05-02
KR20150031298A (ko)	2015-03-23
JP6445972B2 (ja)	2018-12-26
US20130344073A1 (en)	2013-12-26
JP2019048881A (ja)	2019-03-28
MX381048B (es)	2025-04-01
EP4659763A2 (en)	2025-12-10
AU2013277309B2 (en)	2018-03-29
CN115040653A (zh)	2022-09-13
CA2875567C (en)	2023-11-14
DK2861246T3 (en)	2021-04-26
MX2020005700A (es)	2020-09-25
KR20200015952A (ko)	2020-02-13
KR20200116164A (ko)	2020-10-08
EP4659763A3 (en)	2025-12-24
US20260035483A1 (en)	2026-02-05
CN109908352A (zh)	2019-06-21
EP3878865A2 (en)	2021-09-15
AU2013277309A1 (en)	2015-01-22
AU2020202999A1 (en)	2020-05-28
US20220259325A1 (en)	2022-08-18
HUE053727T2 (hu)	2021-07-28
CY1124234T1 (el)	2022-05-27
CN104717975A (zh)	2015-06-17
MX2014015715A (es)	2016-02-05
PT2861246T (pt)	2021-04-05
IL261436B (en)	2021-08-31
CN118924900A (zh)	2024-11-12
IN2015KN00015A (es)	2015-07-31
AU2018204285B2 (en)	2020-02-27
US20260049158A1 (en)	2026-02-19
JP7839502B2 (ja)	2026-04-02
ES2864857T3 (es)	2021-10-14
JP2015521623A (ja)	2015-07-30
EP3878865A3 (en)	2021-12-08
RU2019140356A (ru)	2020-01-27
RS61755B1 (sr)	2021-05-31
PL2861246T3 (pl)	2021-10-25
CA3214532A1 (en)	2013-12-27
IL236327A0 (en)	2015-02-26
NZ629473A (en)	2017-02-24
IL236327B (en)	2019-02-28
HRP20210559T1 (hr)	2021-05-14
LT2861246T (lt)	2021-04-26
KR20220100997A (ko)	2022-07-18
EP2861246A4 (en)	2016-03-23
SI2861246T1 (sl)	2021-08-31
CL2016003297A1 (es)	2017-06-02
RU2015101230A (ru)	2016-08-10
IL261436A (en)	2018-11-04
WO2013192240A3 (en)	2014-07-03
US20240254257A1 (en)	2024-08-01
JP2021006546A (ja)	2021-01-21
JP2026021601A (ja)	2026-02-10
EP2861246A2 (en)	2015-04-22
KR102339315B1 (ko)	2021-12-15
RU2709351C2 (ru)	2019-12-17
CA2875567A1 (en)	2013-12-27
BR112014031522A2 (pt)	2017-08-01
AU2020202999B2 (en)	2022-03-24
EP2861246B1 (en)	2021-01-20

Publication	Publication Date	Title
CL2014003455A1 (es)	2015-04-10	Método para inhibir activación del complemento dependiente de masp-3 y, opcionalmente masp-1 y masp-2, para el tratamiento de diversas enfermedades y trastornos.
IL281793A (en)	2021-05-31	Use of cannabinoids in the treatment of epilepsy
IL283086A (en)	2021-06-30	Use of cannabidiol in the treatment of tuberous sclerosis complex
CL2018002814A1 (es)	2019-02-15	Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
LT3882250T (lt)	2023-05-25	Tetrahidropiranilamino-pirolopirimidinonas, skirtas panaudoti btk nulemtų sutrikimų gydymui
CL2015000873A1 (es)	2015-08-14	Métodos para el tratamiento del síndrome de alport.
IL256166B (en)	2020-10-29	Compounds for use in treating neuromuscular disorders
EP3122414A4 (en)	2017-12-27	Venous disease treatment
PL3157511T3 (pl)	2019-02-28	Zastosowanie kannabinoidów w leczeniu padaczki
PT4000608T (pt)	2026-03-05	Composição farmacêutica, métodos para o tratamento e suas utilizações
DK3212233T3 (da)	2020-07-27	Kombinationsterapi til behandling af sygdom
LT3139925T (lt)	2022-01-25	Valbenazino dozavimo režimas, skirtas gydyti hiperkinetinio judėjimo sutrikimus
SI3122878T1 (sl)	2019-05-31	MRNA terapija za zdravljenje očesnih bolezni
PT3185957T (pt)	2022-09-05	Patisiran para utilização no tratamento de amoloidose mediada por transtirretina
HUE059303T2 (hu)	2022-11-28	Acetilkolin-észteráz-gátlók bõrbetegségek kezelésére
LT3292875T (lt)	2020-08-25	Kompozicijos ir būdai, skirti ligų gydymui
HRP20190194T1 (hr)	2019-04-19	17a,21-diesteri korteksolona, namijenjeni liječenju tumora
IL247354A0 (en)	2016-11-30	Treatment of conditions associated with hyperinsulinaemia
HUE051296T2 (hu)	2021-03-01	Benzoxazinon-származékok bõrbetegségek kezelésére
CL2015000926A1 (es)	2015-08-28	Proceso para la elaboración de compuestos para el tratamiento del cancer derivados de azetidin-1-il-metanona y compuestos intermediarios.
BR112017002318A2 (pt)	2018-07-17	combinações de fármacos para tratar mieloma múltiplo.
LT2961426T (lt)	2019-12-27	Centrinės nervų sistemos susirgimų gydymas, per nosį įvedant imunoglobuliną g
DK3125874T3 (da)	2021-03-22	Et terapeutisk middel til anvendelse i behandlingen af infektioner
HUE051295T2 (hu)	2021-03-01	Módosított fibroblaszt növekedési faktorok-1 szembetegségek kezelésére
DK3307277T3 (da)	2020-12-07	Enkeltstrengede oligonukleotider til anvendelse i medicinsk behandling af hudlidelser